MODUR VIJAY 4
4 · Eloxx Pharmaceuticals, Inc. · Filed Apr 2, 2021
Insider Transaction Report
Form 4
MODUR VIJAY
HEAD OF R&D
Transactions
- Award
Stock Options (Right to Buy)
2021-04-01+711,619→ 711,619 totalExercise: $3.36Exp: 2031-04-01→ Common Stock (711,619 underlying) - Award
Restricted Stock Units
2021-04-01+44,683→ 219,326 total→ Common Stock (44,683 underlying) - Award
Restricted Stock Units
2021-04-01+174,643→ 174,643 total→ Common Stock (174,643 underlying)
Footnotes (3)
- [F1]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- [F2]The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan and will vest in full on December 1, 2021, subject to the Reporting Person's continued employment or other service with the Issuer, which vesting may be accelerated in connection with certain qualifying terminations of employment or in connection with a corporate transaction. Promptly following vesting, and in any event on or prior to December 31, 2021, each restricted stock unit will be settled by delivery of one share of the Issuer's common stock to the Reporting Person.
- [F3]The stock options were issued pursuant to the Issuer's 2018 Equity Incentive Plan. The stock options vest and become exercisable over a four-year period, with one-fourth of the Issuer's shares of common stock underlying the options vesting on April 1, 2022, and with the remainder vesting in twelve equal quarterly installments thereafter, subject to Reporting Person's continued employment or other service with the Issuer on each applicable vesting date, which vesting may be accelerated in connection with certain qualifying terminations of employment or in connection with a corporate transaction.